Trial results for Nivolumab plus Relatlimab in patients with Metastatic Uveal Melanoma were posted on ClinicalTrials.gov on 2025-02-13. The study reported an Objective Response Rate (ORR) of 7.7% for the combination treatment.
Background
The combination of nivolumab and relatlimab was studied in patients with Metastatic Uveal Melanoma.
Trial design
This completed Phase 2 trial (NCT04552223) enrolled 27 participants with Metastatic Uveal Melanoma. The study investigated a combination treatment of nivolumab and relatlimab with the purpose of testing for tumor reduction.
Key results
The trial measured the Objective Response Rate (ORR) for the Nivolumab Plus Relatlimab Group. The reported ORR was 7.7% of participants.
What this means
The observed Objective Response Rate of 7.7% indicates the proportion of participants who experienced tumor reduction with the combination of nivolumab and relatlimab in this study population of patients with Metastatic Uveal Melanoma.
Source
The information regarding these trial results was obtained from ClinicalTrials.gov, a public database of clinical studies. The results for study NCT04552223, titled "Nivolumab Plus Relatlimab in Patients With Metastatic Uveal Melanoma," were posted on 2025-02-13 on clinicaltrials.gov.